Vera Therapeutics, Inc.

For the period ended Dec 31, 2025. Filed Feb 26, 2026.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Feb 26, 2026

VERA$30.61+2.8%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Balance Sheets

(in thousands, except share and per share amounts)

	December 31,
	2025	2024
Assets
Current assets:
Cash and cash equivalents	$354,725	$92,646
Marketable securities	359,864	548,206
Prepaid expenses and other assets, current	14,294	10,366
Total current assets	728,883	651,218
Property and equipment, net	1,374	960
Operating lease right-of-use assets	1,923	3,372
Prepaid expenses and other assets, noncurrent	2,553	131
Total assets	$734,733	$655,681
Liabilities and stockholders’ equity
Current liabilities:
Accounts payable	$21,898	$7,665
Operating lease liabilities	549	1,483
Accrued expenses and other liabilities	31,008	16,223
Total current liabilities	53,455	25,371
Long-term debt	74,838	50,687
Operating lease liabilities, noncurrent	1,919	2,468
Total liabilities	130,212	78,526
Stockholders’ equity
Class A common stock, $0.001 par value; 500,000,000 shares authorized as of December 31, 2025 and December 31, 2024; 71,267,429 and 63,559,858 shares issued and outstanding as of December 31, 2025 and December 31, 2024, respectively	71	64
Additional paid-in capital	1,364,529	1,037,948
Accumulated other comprehensive income	786	393
Accumulated deficit	(760,865)	(461,250)
Total stockholders’ equity	604,521	577,155
Total liabilities and stockholders’ equity	$734,733	$655,681

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.